PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER
Abstract
Authors
E. Suthoff V. Bonthapally P. Hodgkins H. Gunduz-Bruce R. Lasser C. Silber A. Sankoh J. Jonas J. Doherty S. Kanes